NAD injections and weight loss: separating hype from clinical evidence

Step 1: understanding what NAD actually does in the body

NAD is a molecule your cells use to convert food into usable energy. It plays a central role in mitochondrial function and DNA repair, and its levels decline with age. That decline has attracted research interest, not specifically around weight loss, but around metabolic health and longevity more broadly.

Supplement companies have translated this basic science into a marketing narrative: more NAD means better metabolism, which means easier fat burning. The logic sounds neat. The evidence, though, does not carry the chain. Most human studies on NAD precursors (such as NMN or NR, taken orally or by infusion) have been small, short, and focused on markers like blood pressure or insulin sensitivity rather than body weight. None has been powered to demonstrate the kind of weight reduction seen in phase-3 GLP-1 trials.

It is also worth separating two things that often get conflated online: oral NAD precursor supplements and intravenous or intramuscular NAD infusions. Neither has a strong weight-loss evidence base, but the injectable form is sometimes presented as more potent because it bypasses digestion. That does not make it more effective for weight loss, it just means a different delivery route for an effect that has not been robustly demonstrated either way. For a plain overview of the metabolic mechanisms behind licensed weight-loss treatments, the weight-loss treatments overview at nume covers what the trial evidence actually shows.

Step 2: how licensed weight-loss injections differ, mechanistically and evidentially

The comparison matters because people searching for NAD injections are often genuinely trying to lose weight and want to understand their options.

Licensed injectable weight-management medicines work through well-characterised receptor pathways. Mounjaro activates both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite through signals to the brain. Wegovy activates GLP-1 receptors via a similar route. Both have been tested in large phase-3 trials involving thousands of participants, reviewed by the MHRA, appraised by NICE, and prescribed under a framework where a clinician assesses your health before and during treatment. The NICE technology appraisal of tirzepatide (TA1026) summarises the evidence base that informed its recommendation.

NAD injections have no equivalent regulatory pathway for weight loss. They are not licensed for it. No prescriber in the UK is recommending them as a weight-management treatment under clinical guidelines. If you have seen them offered at wellness clinics or via social media sellers, it is worth asking what clinical oversight sits behind the offer, and whether the price covers any medical assessment at all. A broader look at what weight-loss injections actually involve is a useful starting point if you are trying to sort credible options from noise.

Step 3: what the evidence gap means in practice

Absence of evidence is not the same as evidence of harm, but it does mean there is no clinical basis on which to recommend NAD injections for weight loss. The MHRA has not licensed any NAD product for weight management. NICE has not appraised one. The NHS does not offer it.

What this means practically: if you spend money on NAD injections hoping to lose weight, you are essentially running an n=1 experiment with your own body and budget, with no prescriber monitoring what happens. That is a different situation from using a licensed medicine with a defined dose schedule, a Patient Information Leaflet, a clinical team available seven days a week, and a regulatory framework that required years of trial data before a single pen reached a pharmacy shelf.

Some people ask whether NAD might be useful alongside a GLP-1 medicine. This is a question for your prescriber, not something to self-manage. If you are already on a licensed weight-loss injection or considering starting one, the prescriber who reviews your consultation is the right person to raise it with. Combining unregulated injectable products with prescription medicines without clinical oversight is not advisable. For people with specific health conditions (including PCOS or MS) the eligibility picture for licensed options is worth understanding separately.

Step 4: finding a clinical route that is actually supported by evidence

If weight loss is the goal, the most evidence-backed route currently available in the UK is a GLP-1 or dual GIP/GLP-1 medicine prescribed after clinical assessment. Average weight reductions in the pivotal trials ran to 15–22% of body weight over 68–72 weeks, depending on the medicine and dose, as reported in the SURMOUNT-1 paper published in the New England Journal of Medicine and the corresponding STEP 1 data for semaglutide.

At nume, the process is straightforward. A free consultation is reviewed the same day by a real prescriber, a GPhC-registered Independent Prescriber reads your answers, not software. If treatment is clinically suitable and you order before noon, your pen is dispatched the same day and arrives via DPD the next working day in plain, unbranded packaging, with tracking on your phone. There are no hidden charges: consultation, prescription, delivery and seven-day aftercare are all included.

Understanding how licensed injection prices are structured is worth doing before committing to anything, whether through nume or elsewhere. And if exercise, liver health, or hair changes are on your mind alongside weight loss, those topics have their own dedicated pages too, including how exercise fits with injection-based treatment and what the evidence says about liver health. Our clinical team can answer questions that go beyond what any web page can cover. If you are ready to explore a licensed, clinically supervised route, you can start your free consultation today.